Somatrogon for treating growth disturbance in children and young people aged 3 years and over (TA863)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 February 2023
Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency (HST7)Product type:GuidanceProgramme:Highly specialised technologies guidancePublished: 7 February 2018
Faltering growth: recognition and management of faltering growth in children (NG75)Product type:GuidanceProgramme:NICE guidelinePublished: 27 September 2017
Human growth hormone (somatropin) for the treatment of growth failure in children (TA188)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 May 2010
Somapacitan for treating growth hormone deficiency in children [ID6178]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Somapacitan for treating growth failure associated with being small for gestational age, Noonan syndrome or idiopathic short height TSID 12070Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC